Detalhe da pesquisa
1.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Oncologist
; 2024 Mar 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38520745
2.
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Oncologist
; 27(2): 87-e115, 2022 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35641222
3.
The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation.
Int J Mol Sci
; 23(13)2022 Jun 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35806325
4.
Subcutaneously anchored securement for peripherally inserted central catheters: Immediate, early, and late complications.
J Vasc Access
; 24(1): 82-86, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34137321
5.
Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients.
J Vasc Access
; 24(1): 87-91, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34148394
6.
Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.
In Vivo
; 35(5): 2941-2945, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34410991
7.
Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report.
Onco Targets Ther
; 11: 8945-8950, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30573982
8.
Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience.
Oncotarget
; 9(20): 15340-15349, 2018 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-29632648
9.
Activity of crizotinib over choroidal metastases in non-small-cell lung cancer (NSCLC)-ALK rearranged: a case report.
BMC Res Notes
; 7: 589, 2014 Sep 02.
Artigo
Inglês
| MEDLINE | ID: mdl-25178493